 DEER PARK, Ill., June 15, 2021 GLOBE NEWSWIRE -- Eton Pharmaceuticals, Inc Nasdaq: ETON, the U.S. marketer of ALKINDI SPRINKLE, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossjects ZENEO hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis. 